Sumitomo Pharma Co., Ltd. (TYO:4506)
1,345.00
+50.00 (3.86%)
Aug 10, 2026, 3:30 PM JST
Sumitomo Pharma Employees
Sumitomo Pharma had 4,980 employees as of March 31, 2024. The number of employees decreased by 1,270 or -20.32% compared to the previous year.
Employees
4,980
Change (1Y)
-1,270
Growth (1Y)
-20.32%
Revenue / Employee
123.90M JPY
Profits / Employee
29.40M JPY
Market Cap
603.36B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2024 | 4,980 | -1,270 | -20.32% |
| Mar 31, 2023 | 6,250 | -737 | -10.55% |
| Mar 31, 2022 | 6,987 | 165 | 2.42% |
| Mar 31, 2021 | 6,822 | 365 | 5.65% |
| Mar 31, 2020 | 6,457 | 317 | 5.16% |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Eisai | 10,543 |
| Shionogi & | 6,223 |
| Tsumura & Co. | 4,923 |
| Towa Pharmaceutical | 4,923 |
| Sawai Group Holdings | 3,630 |
| Nippon Shinyaku | 2,309 |
| KYORIN Pharmaceutical | 1,982 |
| Kissei Pharmaceutical | 1,786 |
Sumitomo Pharma News
- 4 days ago - Sumitomo Pharma America Earns 2026-2027 Great Place to Work Certification™ - Business Wire
- 10 days ago - Sumitomo Pharma Earnings Call Transcript: Q1 2027 - Transcripts
- 10 days ago - Sumitomo Pharma Quarterly report: Q1 2027 - Filings
- 10 days ago - Sumitomo Pharma Slides: Q1 2027 - Filings
- 11 days ago - Sumitomo Pharma America Announces Enzomenib (DSP-5336) Receives FDA Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia - Business Wire
- 2 months ago - Sumitomo Pharma America Announces Encouraging Clinical and Translational Data at EHA 2026, Highlighting Investigational Combination Therapy in Relapsed/Refractory Myelofibrosis and New Research Findings in Menin Inhibition in Leukemia - Business Wire
- 2 months ago - Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia - Business Wire
- 2 months ago - Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026 - Business Wire